Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 32, Issue 6, 2013, Pages 644-647

  Orrell, Catherine ^a   Levison, Julie ^b,c   Ciaranello, Andrea ^b   Bekker, Linda Gail ^a   Kuritzkes, Daniel R ^b,c   Freedberg, Kenneth A ^b,c,d   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Genotype; Pediatric; Resistance; Resource limited setting; Virologic failure

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE;

EID: 84879204685     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182829092     Document Type: Article

References (10)

1. National Department of Health. South African National Antiretroviral Treatment Guidelines. 1st ed. Cape Town, South Africa: National Department of Health; 2004 (cited January 25, 2007). Available at: http://www.hst.org.za/ uploads/files/sa-ART-Guidelines1.pdf. Accessed June 12, 2012.
2. World Health Organization. Scaling Up Antiretroviral Therapy in Resource Limited Settings - Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2002. Available at: http://www.who.int/hiv/pub/prev- care/ScalingUp-E.pdf. Accessed June 12, 2012.
3. Luzuriaga K, McManus M, Mofenson L, et al.; PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471-2480.
4. van Zyl GU, van der Merwe L, Claassen M, et al. Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J. 2009;28:1125-1127.
5. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18:156-163.
6. Stanford University HIV Drug resistance Database. Genotypic resistance interpretation algorithm. Available at: http://sierra2.stanford.edu/sierra/ servlet/JSierra. Accessed April 25, 2012.
7. Tolle M, Howard L, Kirk B, et al. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in gaborone, botswana. J Int Assoc Physicians AIDS Care (Chic). 2012;11:260-268.
8. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1449-1454.
9. Wallis CL, Erasmus L, Varughese S, et al. Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national antiretroviral roll-out program. Pediatr Infect Dis J. 2009;28:1123-1125.
10. Taylor BS, Hunt G, Abrams EJ, et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011;27:945-956.